The Section of Gastroenterology in the Department of Medicine is recruiting men and women, between the ages of 18 and 75 years who have been diagnosed with moderate to severe ulcerative colitis (UC) for at least three months. The AMAC study is looking to evaluate the safety and effectiveness of an injectable drug for the treatment of UC and test the hypothesis that treatment with the study drug is superior to placebo in inducing clinical remission at week 12 in subjects with moderate to severe ulcerative colitis. If interested, please contact Guillermina Cruz at (713) 798-8220 or


Guillermina Cruz Guillermina.Cruz@bcm.eduPhone 1: (713) 798-8220
IRB: h-38296




Dec 13, 2016